Histomorphometric Changes by Teriparatide in Alendronate-pretreated Women with Osteoporosis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2010 Feb 6

PMID 20135094

Citations 20

Authors

J J Stepan

D B Burr

J Li

Y L Ma

H Petto

A Sipos

H Dobnig

A Fahrleitner-Pammer

D Michalska

I Pavo

Affiliations

Soon will be listed here.

Abstract

Summary: The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1-34), TPTD) is similar in patients who were either treatment-naïve (TN) or had lower bone turnover initially due to previous alendronate (ALN) therapy.

Introduction: Bone anabolic effects of TPTD in postmenopausal women with osteoporosis may be blunted during the initial phase after switching from ALN to TPTD. To explore the long-term implications, we examined histomorphometric and biochemical markers of bone turnover of patients on TPTD therapy after long-term ALN treatment.

Methods: Paired biopsies were obtained after tetracycline double labeling at baseline and after 24 months of TPTD treatment from 29 ALN-pretreated (64.5 ± 16.4 months) and 16 TN patients. Biochemical markers were measured at baseline, during the treatment, or at study end.

Results: Compared with the baseline, after 24-month TPTD, activation frequency (Ac.F.) and osteoid surface (OS) increased in both groups: 0.11-0.34 cycles per year, 3.96-9.8% in the ALN-pretreated group and 0.19-0.33 cycles per year, 6.2-11.3% (p < 0.05) in the TN group, respectively. Biochemical and histomorphometric markers correlated positively both at baseline and endpoint. Serum amino terminal propeptide of type I procollagen (PINP) correlated with Ac.F. (r = 0.57, p < 0.001 and r = 0.48, p < 0.01) and OS (r = 0.51, p < 0.01 and r = 0.56, p < 0.01) at baseline and endpoint, respectively. Following 3 months of treatment, increases in biochemical markers like PINP predicted the increase in Ac.F. (r = 0.52, p < 0.01) and OS (r = 0.54, p < 0.01) after 24 months.

Conclusions: The increased level of formation is similar in patients who were either TN or had lower bone turnover initially due to previous ALN therapy. Elevated bone formation in postmenopausal women with osteoporosis was sustained over a 24-month period by TPTD. Biochemical markers of bone formation are a good surrogate for the assessment of TPTD effects.

Citing Articles

Exercise for optimizing bone health after hormone-induced increases in bone stiffness.

Hughes J, Guerriere K, Popp K, Castellani C, Pasiakos S Front Endocrinol (Lausanne). 2023; 14:1219454.

PMID: 37790607 PMC: 10544579. DOI: 10.3389/fendo.2023.1219454.

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters.

Sandeep N, Joseph A, Cherian K, Kapoor N, Paul T Ther Adv Endocrinol Metab. 2022; 13:20420188221112903.

PMID: 35923461 PMC: 9340409. DOI: 10.1177/20420188221112903.

Role of bone-forming agents in the management of osteoporosis.

McClung M Aging Clin Exp Res. 2021; 33(4):775-791.

PMID: 33594648 DOI: 10.1007/s40520-020-01708-8.

Effects of Intermittent Administration of Parathyroid Hormone and Parathyroid Hormone-Related Protein on Fracture Healing: A Narrative Review of Animal and Human Studies.

Yamashita J, McCauley L JBMR Plus. 2019; 3(12):e10250.

PMID: 31844831 PMC: 6894727. DOI: 10.1002/jbm4.10250.

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis.

Minisola S, Cipriani C, Della Grotta G, Colangelo L, Occhiuto M, Biondi P Ther Adv Musculoskelet Dis. 2019; 11:1759720X19877994.

PMID: 31632472 PMC: 6778993. DOI: 10.1177/1759720X19877994.

References

Recker R, Weinstein R, Chesnut 3rd C, Schimmer R, Mahoney P, Hughes C . Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004; 15(3):231-7. DOI: 10.1007/s00198-003-1530-0. View

Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D . Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20(6):962-70. DOI: 10.1359/JBMR.050105. View

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L, Gallagher J . Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005; 90(7):3970-7. DOI: 10.1210/jc.2003-1703. View

Khan S, Kanis J, Vasikaran S, Kline W, Matuszewski B, McCloskey E . Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997; 12(10):1700-7. DOI: 10.1359/jbmr.1997.12.10.1700. View

Thompson K, Rogers M, Coxon F, Crockett J . Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol. 2006; 69(5):1624-32. DOI: 10.1124/mol.105.020776. View

Seeman E . Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone. 2007; 41(3):308-17. DOI: 10.1016/j.bone.2007.06.010. View

Arlot M, Meunier P, Boivin G, Haddock L, Tamayo J, Correa-Rotter R . Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20(7):1244-53. DOI: 10.1359/JBMR.050309. View

Eastell R, Krege J, Chen P, Glass E, Reginster J . Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006; 22(1):61-6. DOI: 10.1185/030079905X75096. View

10.

Ensrud K, Barrett-Connor E, Schwartz A, Santora A, Bauer D, Suryawanshi S . Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004; 19(8):1259-69. DOI: 10.1359/JBMR.040326. View

11.

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster D, Hodsman A . Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22(4):495-502. DOI: 10.1359/jbmr.070104. View

12.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

13.

Canalis E, Giustina A, Bilezikian J . Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357(9):905-16. DOI: 10.1056/NEJMra067395. View

14.

Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100(6):1475-80. PMC: 508326. DOI: 10.1172/JCI119668. View

15.

Recker R, Delmas P, Halse J, Reid I, Boonen S, Garcia-Hernandez P . Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2007; 23(1):6-16. DOI: 10.1359/jbmr.070906. View

16.

Nancollas G, Tang R, Phipps R, Henneman Z, Gulde S, Wu W . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005; 38(5):617-27. DOI: 10.1016/j.bone.2005.05.003. View

17.

Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-39. DOI: 10.1056/NEJMoa071408. View

18.

Genant H, Li J, Wu C, Shepherd J . Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom. 2000; 3(3):281-90. DOI: 10.1385/jcd:3:3:281. View

19.

Compston J . Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2006; 40(6):1447-52. DOI: 10.1016/j.bone.2006.09.008. View

20.

Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A . The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18(1):9-17. DOI: 10.1359/jbmr.2003.18.1.9. View